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Effects of Berberine, Chelerythrine, and Sanguinarine on Proliferation 
in Four Human Immortalized Cell Lines 
DAVIDS. SENCHINA1·*, NISARG B. SHAH2 and MARC G. BUSCH1 
1Deparcmenc of Biology, Drake University, Des Moines, IA 
2Pharmacy Program, Drake University, Des Moines, IA 
Bloodroot (Sanguinaria canadensis L., Papaveraceae) is a plane rich in benzophenanchridine (isoquinoline) alkaloids ~uch_ as 
sanguinarine and chelerychrine. Boch isolated alkaloids and whole-tissue rhizome extracts ha:'e demo.nscr:iced zn ~ttro 
anticarcinogenic (antiproliferacive) activity in limited immortalized cell culture models, but the relauve contnbuc1on of vanous 
alkaloid constituents ro whole-tissue extract activity, and whether or not various alkaloids may ace synergiscically, has not been 
investigated. We challenged four immortalized cell lines (Jurkat, K562, Ramos, U937) with various doses of .chelerythr!ne, 
sanguinarine, and berberine (a structurally and functionally similar alkaloid absent from bloodroot), alone and m al\ ~ss1b\e 
combinations, and measured proliferation rates 48 hours pose-treatment. K562 cells were unaffected by all doses of berberme and 
chelerychrine tested, but showed anti proliferative activity at 0. 5 µg/mL sangui?arine. Th.e doses. of sanguinarine necessary. to 
elicit anti-proliferative effects in these experiments matched well with chose seen m whole-Cissue rhizome extracts demonscracmg 
similar anti-proliferative effects. When a 2 µg/mL dose of sanguinarine was tested in all four cell lines, sanguinarine elicited even 
stronger antiproliferacive effects in Jurkat, Ramos, and U937 cells compared to K562 cells; these three cell lines also 
demonstrated reduced proliferation in the presence of chelerythrine at a dose of 1 µg/mL whereas K562 did not. Ac the doses 
tested here, berberine had no direct effect on proliferation. These results suggest chat sanguinarine may be responsible for the 
bulk of anticarcinogenic activity from bloodroot whole-tissue rhizome extracts, but that ocher alkaloids such as chelerythrine 
may also play important roles contingent on cell type. 
INTRODUCTION 
Bloodroot (Sanguinaria canadensis L.) is an herbaceous perennial 
found in eastern and central North America (Graf et al., 2007; 
Figure 1). Botanically, it is the only member of the genus 
Sanguinaria. This genus belongs to the poppy family (Papaver-
aceae) which is well-known for its medicinal compounds. The 
Native American tradition of using bloodroot as a medicinal 
plant has changed but continued into the twenty-first century 
where it has had two primary indications: as a dental care agent 
(Hong et al. 2005) and an anti-skin cancer agent (Moran and 
Helm 2008; DeStefano et al. 2009; Wang and Warshaw 2012). 
More recent research suggests it may be anticarcinogenic against 
other non-dermal cells types, such as breast, intestinal, and 
lymphatic cancer cells (Han et al. 2008; Kim et al. 2008; Choi 
et al. 2009a; Mazzio and Soliman 2009; Lee et al. 2012). 
The purported primary bioaccive molecule from bloodroot 
is sanguinarine, a benzophenanthridine (isoquinoline) alkaloid 
which is the most prevalent alkaloid in bloodroot extracts 
(Campbell et al. 2007; De Stefano et al. 2009). It is also found in 
ocher members of Papaveraceae as well as the fumitory family 
(Fumariaceae), the buttercup family (Ranunculaceae), and the 
citrus family (Rutaceae) (Vecera et al. 2007). Most research has 
focused on the activity of chis lone molecule in in vitro cell culture 
models (Choi et al. 2009b; Mishra et al. 2009; Vrba et al. 2009) 
where it has conclusively shown anticarcinogenic effects that 
appear to be specific towards cancerous cells and not healthy cells 
(Ahmad et al. 2000). Our team has shown similar activity by 
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whole-tissue extracts from bloodroot rhizomes, in which sanguinarine 
was the most abundant alkaloid; in our model, those extracts reduced 
proliferation of the human myelogenous leukemia cell line K562 
while stimulating proliferation of peripheral blood mononuclear cells 
from healthy young human adults (Senchina et al. 2009a). However, 
formal analyses of the proliferation data (and accompanying cycokine 
secretion data) from that and other srudies (Senchina et al. 2009b; 
Senchina et al. 2012) collectively suggest that sanguinarine content 
alone may not account for all observed immunoodulatory effects. 
Whether or not other alkaloids present in the plant (or other 
scrucrurally-similar compounds found in other plant genera) may 
contribute to such effects is unknown. Chelerythrine is one such 
candidate alkaloid also found in bloodroot (Graf et al. 2007), other 
members of Papaeveraceae, and two other families (Fumariaceae and 
Rutaceae; Zdarilova et al. 2006). Chelerythrine demonstrates similar 
anti-cancer properties as sanguinarine (Vogler et al. 2009; Hammer-
ova et al. 2011). Whether alkaloids such as chelerychrine and 
sanguinarine may interact in a synergistic or combinatorial manner 
has not been directly demonstrated; however, Larsson et al. (2009) 
showed chat sanguinarine weakly synergizes with other chemother-
apeutic drugs in vitro. 
As an attempt to "bridge the gap" between those studies that 
examined cell proliferation or apoptosis utilizing alkaloid-rich 
bloodroot extracts and chose using sanguinarine alone, a series of 
experiments were undertaken. The anti-proliferative activity of 
both sanguinarine and chelerythrine were investigated, as well as 
a structurally-similar third alkaloid (berberine) which is not 
present in bloodroot but is found in ocher closely related plant 
families. Four immortalized cell lines representative of the human 
immune system (Jurkat, K562, Ramos, U937) were tested 
against the three alkaloids. The aim of the first experiment was to 
determine if the three alkaloids had similar or different effects on 
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Fig. 1. Bloodroot (Sanguinaria canadensis L) from Carr Woods in Ames, Iowa, spring 2013. Left: Plant in anthesis with newly-emerged 
leaves clasping the petiole, approximately 9 cm tall (April}. Right: Plant fruiting (see leaf center) with more mature leaves, after a late 
snowstorm (May). 
K562 cell proliferation at various doses including those found m 
whole-tissue rhizome extracts; an ancillary aim of rhe first 
experiment was to determine if the alkaloids acted synergistically. 
The aim of the second experiment was to determine if other cell 
lines responded similarly to K562 cells under the same treatment 
doses. For both experimental series, cells were cultured with each 
alkaloid, alone or in all possible combinations, for 48 hours after 
which time cells were counted and compared to baseline. 
METHODS 
K562 cells (representing undifferentiated granulocytes) were 
generously provided by Dr. Joan E. Cunnick (Iowa State 
University). Jurkat E6-l (representing T cells), Ramos RAl 
(representing B cells), and U93 7 (representing monocytes) cell 
lines were purchased from ATCC. All four cell lines are non-
adherent in culture. The culture media was CRPMI, based on a 
recipe of 440 mL RPMI (GIBCO) supplemented with HJ mL of 
penicillin/streptomycin (GIBCO) and 50 mL fetal bovine serum 
(Mediatech). Berberine, chelerythrine, and sanguinarine (Figure 2; 
obtained from Sigma-Aldrich) were diluted into stock concentra-
tions (see below), stored at -80°C, and tested within two months 
of preparation. Some of these compounds are photosensitive and 
require being kept in dark conditions; however, aqueous solutions 
of dilutions stored at --80°C are biochemically srable and maintain 
immunomodulatory activity with long-term light-protected 
storage at -80°C (Senchina et al. 2009b). 
Cell cultures were grown for each of the four cell lines such 
that approximately 150 mL of cell culture at 1.0 X l 05 cells/mt 
was established prior to testing. For the experiments, cells were 
partitioned as 5 mL cultures, with three flasks established for each 
of eight different treatment conditions: (1) control (media alone), 
(2) berberine (3) chelerythrine alone, sanguinarine alone, 
(5) bcrberine + chelerythrine, (6) berberine + sanguinarine, (7) 
chelerythrine + sanguinarine, (8) and all thee alkaloids together. 
The initial concentrations of sanguinarine and chelerythrine for 
stock solutions were chosen based on average concentrations found 
in several batches of rhizome extracts, including those identified 
previously (Senchina et al. 2009a) and additional rhizome extracts 
currently under experimentation: sanguinarine at 0.8 ~tg/mL and 
chelerythrine at OA µg/mL For berberine, we arbitrarily chose 
to test it at the same concentration as chelerythrine. Final 
concentrations of each alkaloid in the wells at the 1 X concentration 
were as follows: 0.01 µg/mL for both berberine and chelerythrine, 
and 0.02 µg/mL for sanguinarine. Cells were variously treated with 
lX, lOX, or 100X doses. Cultures were grown under standard 
incubation conditions 5% cob humidified) for 48 hours. 
After incubation, number and viability of celis post-treatment 
were assessed manually using a hemacytometer and Trypan blue 
staining. Results were averaged across the three replicates for ail 
eight conditions. 
One-way ANOV A was used to check for significant differences in 
proliferation across treatment conditions (PAS\l(! 17 .0, SPSS Inc.); 
when a main effecr of treatment was uncovered, significance between 
pairwise comparisons was determined using LSD. Signifi-
cance was defined as ::x<0,05 whereas a trend towards significance 
was defined as O.Cl5<-:x<OJ. When multiple comparisons were 
used within an ANOV A, a correction was made by dividing the 
starting et-value of 0.05 the number of comparisons and 
redefining significance based on the corrected p-value. 






Fig. 2. Benzophenanthridine alkaloids used in this study. 
According to Chaturvedi et al. 0997), all three are considered 
chemical analogues of each other, and chelerythrine and sanguin-
arine are considered structural homologues. Sanguinarine and 
chelerythrine are produced by bloodroot whereas berberine is not. 
Structures were drawn using ChemSketch (ACD/Labs). 
RESULTS 
To determine the concentration of alkaloids necessary to 
influence cell proliferation, initially only the K562 cells were 
tested at 1 X (representing those found in rhizome ethanol 
extracts based on Senchina et al. [2009a}), 10 X, and 100 X 
concentrations (Table 1). There was a main effect of treatment 
(p<0.001). Across all doses tested, only sanguinarine was able to 
significantly diminish cell proliferation as compared to control, and 
only at the lOOX concentration (2.0 µg/mL). This effect was 
significant when sanguinarine was used alone or in combination with 
one or both other alkaloids (p<0.001 all cases). There was also a 
trend for the combination of berberine and chelerythrine to diminish 
proliferation at lOOX concentrations (1.0 µg/mL each; p=0.001). 
To better understand the dose-response relationship between 
sanguinarine and K562 proliferation, sanguinarine alone was 
tested at 25X, SOX, 75X, and lOOX concentrations (Figure 3). 
There was a main effect of treatment (p<0.001) such that 
proliferation was significantly lower at all treatment doses 
compared to the vehicle control (all p<0.001), with the 25X 
dose being 0.5 µg/mL. The collective data demonstrated the 
expected dose-response relationship (e.g., average proliferation 
values decreased as the concentration of sanguinarine increased). 
However, there were no significant differences when the various 
treatments were compared against each other. 
To determine if other cell lines responded to the three 
alkaloids similarly to how K562 cells had, cultures of Jurkat, 
Ramos, and U937 cells were tested in the same manner using 
only the lOOX alkaloid concentrations. Although all the results 
from all three cell lines are presented together in Table 2, 
separate ANOVA were run for each cell type independently of 
others. There was a main effect of treatment for all three cell lines 
(all p<0.001); p-values presented in the remainder of this 
paragraph reference comparisons to control. Berberine alone had 
no effect on cell proliferation in any of the three cell lines. 
Chelerythrine alone or combined with berberine diminished cell 
proliferation in all three cell lines (p::;0.003). Sanguinarine alone 
caused complete cell culture death in all three cell lines 
(p::;Q.001). Interestingly, the effects of sanguinarine on prolif-
eration were sometimes different when sanguinarine was used in 
combination with other alkaloids, and this phenomenon varied 
by cell type. In the case of Jurkat and U937 cells, sanguinarine 
combined with one or both other alkaloids either resulted in 
complete cell culture death or cell culture stasis (p::;0.001). The 
results with Ramos cells were more complex. Compared to 
control, the proliferative response of Ramos cells was significantly 
lower when sanguinarine was administered with one or both 
other alkaloids (p<0.001). However, administration of sanguin-
arine in combination with one or both other alkaloids did not 
result in complete cell culture death, as was the case when 
sanguinarine was administered alone. 
Table 1. Proliferative response of K562 cells to three alkaloids at lX, lOX, and lOOX concentrations (starting 
concentrations of 0.4 µg/mL for berberine and chelerythrine, and 0.8 µg/mL for sanguinarine). Each experiment was 
performed in triplicate. Values are cell counts (expressed as 1.0 X 105 cells/mL) ± standard error. Asterisks (*) indicate 
statistically significant differences of treatment compared to control within the same column (all p<0.001). 
Relative Concentration 
IX lOX IOOX 
Control 14.9 + 1.0 14.9 + 1.0 14.9 + 1.0 
Berberine 14.9 + 1.2 13.4 + 1.5 16.6 + 0.8 
Chelerythrine 17.0 + 0.9 18.1 + 2.4 16.0 + 1.1 
Sanguinarine 14.4 + 1.5 15.8 + 3.5 1.8 + 0.2* 
Berberine + Chelerythrine 14.8 + 0.3 15.4 + 0.5 14.5 + 1.0 
Berberine + Sanguinarine 13.9 + 0.8 12.7 + 0.2 3.4 + 0.5* 
Chelerythrine + Sanguinarine 15.0 ± 0.9 15.5 + 0.7 2.4 + 0.3* 
All 3 Alkaloids 11.2 + 0.8 11.7 + 1.3 3.6 ± 0.4* 
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Table 2. Proliferative response of Jurkat, Ramos, and U937 cells to three alkaloids at lOOX concentrations. Each 
experiment was performed in triplicate. Values are cell counts (expressed as 1.0 X 105 cells/mL) ± standard error. 
BL=below limits of detection. The dagger <t> indicates data from Table 1 (lOOX concentration) included again here for 
comparison. Asterisks (*) indicate statistically significant differences of treatment compared to control within the same 





Berberine + Chelerythrine 
Berberine + Sanguinarine 
Chelerythrine + Sanguinarine 
All 3 Alkaloids 
DISCUSSION 
Jurkat 
30.7 ± 7.6 
23.3 ± 3.5 
1.3 ± 0.8* 
BL* 
1.3 ± 0.8* 
1.0 ± O* 
BL* 
BL* 
The aims of this experimental series were threefold: (1) to 
compare the effects of berberine, chelerythrine, and sanguinarine, 
alone and in all possible combinations and in various doses, on 
proliferation of KS62 cells; (2) to characterize the response of 
other immortalized cell lines relative to KS62 cells; and (3) to 
determine if alkaloids act synergistically to influence prolifera-
tion. Findings from these experiments confirmed and extended 
previous work from our lab and others. 
To address aim #1, the effects of various doses of all three 
alkaloids on KS62 cell proliferation was determined (Table 1 and 
Figure 3). KS62 cell proliferation was negatively influenced by 
sanguinarine but not berberine or chelerythrine. Sanguinarine 
concentrations between O.S-2.0 µg/mL were necessary to observe 
statistically significant reductions in cell proliferation, whereas 
concentrations of 0.2 µg/mL or less had no effect on proliferation. 
Previously, our lab demonstrated that whole-tissue extracts from 
bloodroot rhizomes were able to diminish proliferation of KS62 
107 








:I 105 z 
Fig. 3. Proliferative response of K562 cells to sanguinarine in a 
dose-response test. Each experiment was performed in triplicate. 
Values are cell counts (expressed as cells/mL) ± standard error. 
K562t 
14.9 ± 1.0 
16.6 ± 0.8 
16.0 ± 1.1 
Cell Line 
1.8 ± 0.2* 
14.S ± 1.0 
3.4 ± 0.S* 
2.4 ± 0.3* 
3.6 ± 0.4* 
Ramos 
27.0 ± 6.5 
27.3 ± 4.7 
s.o ± 1.3* 
BL* 
6.3 ± 0.3* 
2.0 ± 1.S* 
2.3 ± 1.2* 
2.0 ± 0.6* 
U937 
21.3 ± 4.9 
24.7 ± 8.3 
3.7 ± 2.7* 
BL* 




cells yet stimulate proliferation of peripheral blood mononuclear 
cells obtained from healthy young human adults, and that 
sanguinarine was the principal component of those extracts 
(Senchina et al. 2009a). In that previous study, a cold water 
extract negligibly influenced KS62 proliferation, whereas a hot 
water extract reduced the cell population to 11 % of the control 
value, and an ethanol extract resulted in complete cell culture 
death. Sanguinarine concentrations for the three extracts once 
diluted in cell culture were 0.17, 1.09, and 2.93, µg/mL, 
respectively. Thus, the sanguinarine content of the hot water and 
ethanol rhizome extracts used previously fall within the 
0.5-2.0 µg/mL range determined in this experiment to be 
necessary to see effects. The SOX dose of sanguinarine (1.0 µg/ 
ml) is most similar to the hot water extract used previously; 
notably, the SOX dose of sanguinarine reduced the cell 
population to 14% of the control value, consistent with the 
effect of the hot water extract. These results suggest that, at least 
in the KS62 model, sanguinarine alone may explain the anti-
proliferative effect seen from whole-tissue rhizome extracts. 
To address aim #2, the effects of the lOOX concentrations 
of all three alkaloids, alone or in various combinations, on 
proliferation of Jurkat, Ramos, and U937 cells was ascertained 
(Table 2). Compared to K562 cells, other immortalized cell lines 
may be more susceptible to the anti-proliferative effects of 
alkaloids. Once again, berberine had no effect in any of the cell 
lines. Chelerythrine (1.0 µg/mL in the 100 X dose) negatively 
impacted proliferation in all three cell lines (unlike in KS62 
cells). Sanguinarine demonstrated an even more pronounced anti-
proliferative effect than in K562 cells. Sanguinarine combined 
with one or more other alkaloids resulted in complete cell culture 
death or cell culture stasis in both Jurkat and U937 cells; by 
contrast, in Ramos cells sanguinarine showed a stronger anti-
proliferative effect when it was used alone, and a lesser effect 
when it was combined with other alkaloids. 
Why Ramos and KS62 cells are less sensitive to andJurkat and 
U93 7 cells are more sensitive to the effects of sanguinarine, and 
why Jurkat, Ramos, and U937 cells are more sensitive to 
chelerythrine than KS62 cells is not immediately clear. 
Immortalized cells are indefinitely replicating cancerous cells 
derived clinically; each cell line originally started as normal 
human immune cells. Hematopoetically, Jurkat and Ramos cells 
(originally T and B cells, respectively) derive from the common 
lymphoid progenitor whereas KS62 and U937 cells (originally 
undifferentiated granulocytes and monocytes, respectively) derive 
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from the common myeloid progenitor. Thus, there is nothing in 
the hematopoetic lineages of these cell lines that suggests a 
developmental relationship. 
Berberine, chelerythrine, and sanguinarine are structurally 
similar (Figure 2). Both chelerythrine and sanguinarine are 
produced by bloodroot whereas berberine is not; notably, both 
chelerythrine and sanguinarine demonstrated anti-proliferative 
activity whereas berberine did not. Berberine was chosen as a 
comparison alkaloid because it is structurally similar to bloodroot 
alkaloids and produced naturally by other plant taxa, including 
other members of the poppy family (lsrailov et al. 1986; 
Takemura et al. 2010) as well as eight other plant families 
(Philogene et al. 1984). However, berberine has shown anticancer 
activity in alternative models including K562 cells (Pazhang 
et al. 2011) and U937 cells (Jantova et al. 2007). Differences 
between our work and others' are likely due to variances in 
experimental models chosen, but it is important to note that 
since berberine does not naturally occur in bloodroot, it is 
perhaps not surprising to see that it behaved differently than 
bloodroot alkaloids in our model. 
To address aim #3, alkaloids were tested alone and in various 
combinations in all four cell lines (Table 2). No synergistic 
effects were apparent in our investigation in any of the examined 
cell lines; however, this may be an artifact of the experimental 
design and complex interplay between different alkaloids or cell 
types. For example, in Jurkat and U937 cells, sanguinarine 
showed such strong effects across all conditions that it possibly 
"masked" or "overrode" any interplay between it and cheler-
ythrine. By contrast, chelerythrine appeared to diminish the anti-
proliferative effects of sanguinarine against K562 and Ramos 
cells. The difference in sanguinarine-treated wells versus wells 
treated with one or more other alkaloids were not statistically 
significant in either the K562 or Ramos cells at lOOX 
concentrations after correcting the ex value for multiple 
comparisons. Given the structural similarity between the three 
alkaloids, it is possible that chelerythrine and sanguinarine bind 
to the same cell surface receptors and may compete with each 
other for docking sites. It is conceivable that if chelerythrine 
outcompetes sanguinarine for binding sights yet has less 
anticarcinogenic activity, it could diminish the effects of 
sanguinarine when the two are administered simultaneously in 
culture. Differences seen across the different cell lines may be 
explained by differences in presence/absence, quantity, or timing 
of expression of those receptors between the cell types studied 
here. Further experiments are necessary to clarify interactions 
between alkaloids and the exact identity of the alkaloid receptor. 
The clinical utility of bloodroot alkaloids against cancer is 
reaffirmed by these results, as both sanguinarine and cheler-
ythrine demonstrated anti-proliferative activity against two or 
more cell lines (and has been demonstrated previously in other 
cell lines). To the best of our knowledge, this is the first report of 
the effects of: berberine on J urkat and Ramos cells; chelerythrine 
on K562, Ramos, and U937 cells; and sanguinarine on Jurkat, 
K562, and Ramos cells. Reports elsewhere have addressed the 
effects of berberine on K652 (Pazhang et al. 2011) and U937 
(Jantova et al. 2007) cells, chelerythrine on Jurkat cells (Vogler 
et al. 2009), and sanguinarine on U93 7 cells (Han et al. 2008). 
This study has several limitations. Only limited doses were 
used, and it is possible that higher or lower doses would elicit 
alternate results. We examined only three alkaloids, and only two 
of which were present in bloodroot; although several other 
bloodroot alkaloids have been characterized (and more are likely 
to be discovered), they were not readily commercially available at 
the time of the study. Our study examined only immortalized 
cell lines representative of the human immune system, so it is 
unknown how generalizable these results are to other somatic cell 
types or primary cells. 
Altogether, these results suggest that benzophenanthridine 
alkaloids may impact on cancer cell proliferation in a complex 
manner contingent on cancer cell type, dose, and presence/ 
absence of other alkaloids (and possibly other phytochemicals). Of 
the three alkaloids, sanguinarine demonstrated the strongest anti-
proliferative effect whereas berberine demonstrated none, and 
chelerythrine elicited heterogeneous effects contingent on cell 
type tested. While our findings should strongly encourage 
medical scientists to continue their investigations of bloodroot 
extracts and alkaloids in cancer models, caution is also necessary 
as some adverse effects have been reported (Cienki and Zarat 
2010; Childress et al. 2011; Vlachojannis et al. 2012). Thus, it is 
imperative that scientists redouble their efforts at educating 
medical practitioners and the lay public alike as to both the 
potential clinical advantages and potential clinical adverse effects 
of bloodroot extracts or constituent alkaloids. 
ACKNOWLEDGMENTS 
This study was funded by Iowa Academy of Sciences grant 
#10-04 awarded to DSS. All three authors contributed 
experimental data. Structures and figures were produced by 
MGB and DSS. DSS wrote the paper and took the photographs. 
REFERENCES 
AHMAD, N., S. GUPTA, M. M. HUSAIN, K. M. HEISKANEN, and 
H. MUKHTAR. 2000. Differential antiproliferative and apoptotic 
response of sanguinarine for cancer cells versus normal cells. Clinical 
Cancer Research 6:1524-1528. 
CAMPBEil., S., J. AFFOLTER, and W. RANDLE. 2007. Spatial and 
temporal distribution of the alkaloid sanguinarine in Sanguinaria 
canadensis L. (Bloodroot). Economic Botany 61:223-234. 
CHATURVEDI, M. M., A. KUMAR, B. G. DARNAY, G. B. N. 
CHAINY, S. AGARWAL, and B. B. AGARWAL. 1997. Sanguin-
arine (pseudochelerythrine) is a potent inhibitor of NF-KB activation, 
IKBIX phosphorylaytion, and degradation. Journal of Biological 
Chemistry 272:30129-30134. 
CHILDRESS, M. 0., R. C. F. BURGESS, C. H. HOLLAND, and H. R. 
GELB. 2011. Consequences of intratumoral injection of a herbal 
preparation containing blood root (Sanguinaria canadensis) extract in 
two dogs. Journal of the American Veterinary Medical Association 
239:374-379. 
CHOI, W. Y., C. Y. JIN, M. H. HAN, G. Y. KIM, N. D. KIM, W. H. 
LEE, S. K. KIM, and Y. H. CHOI. 2009a. Sanguinarine sensitizes 
human gastric adenocarcinoma AGS cells to TRAIL-mediated 
apoptosis via down-regulation of AKT and activation of caspase-3. 
Anticancer Research 29:4457-4465. 
CHOI, Y. H., W. Y. CHO, S. H. HONG, S. 0. KIM, G.-Y. KIM, 
W. H. LEE, and Y. H. YOO. 2009b. Anti-invasive activity of 
sanguinarine through modulation of tight junctions and matrix 
metalloproteinase activities in MDA-MB-231 human breast carcino-
ma cells. Chemico-Biological Interactions 179:185-191. 
CIENKI, J. J. and L. ZARET. 2010. An Internet misadventures: 
bloodroot salve toxicity. Journal of Alternative and Complementary 
Medicine 16:1125-1127. 
DESTEFANO, I., G. RASPAGLIO, G. F. ZANNONI, D. TRAVA-
GLIA, M. G. PRISCO, M. MOSCA, C. FERLINI, G. SCAMBIA, and 
D. GALLO. 2009. Antiproliferative and antiangiogenic effects of the 
benzophenanthridine alkaloid sanguinarine in melanoma. Biochem-
ical Pharmacology 78:1374-1381. 
GRAF, T. N., K. E. LEVINE, M. E. ANDREWS,). M. PERLMUT-
TER, S.). NIELSEN,). M. DAVIS, M. C. WANI, and N. H. 
OBERLIES. 2007. Variability in the yield of benzophenanthridine 
BLOODROOT ALKALOIDS AND CELL PROLIFERATION 27 
alkaloids in wildcrafted vs. cultivated bloodroot (Sanguinarina 
canadensis L.) Journal of Agricultural and Food Chemistry 
55:1205-1211. 
HAMMEROVA, J., S. ULDRIJAN, E. TABORSKA, and I. SLANI-
NOV A. 2011. Benzo[c}phenanthridine alkaloids exhibit strong anti-
proliferative activity in malignant melanoma cells regardless of their 
p53 status. Journal of Dermatological Science 62:22-35. 
HAN, M. H., Y. H. YOO, and Y. H. CHOI. 2008. Sanguinarine-induced 
apoptosis in human leukemia U937 cells via Bcl-2 downregulation and 
caspase-3 activation. Chemotherapy 54:157-165. 
HONG, S.J., S. S.JEONG, and K. B. SONG. 2005. Effects of sanguinaria 
in fluoride-containing dentrifices on the remineralisation of subcuta-
neous lesion in vitro. International Dental Journal 55:128-132. 
ISRAILOV, I. A., V. A. CHELOMBITKO, and L. E. NAZAROVA. 1986. 
Argemone alkaloids. Chemistry of Natural Compounds 22:742-743. 
JANTOV A, S., L. CIP AK, and S. LET ASIOV A. 2007. Berberine 
induces apoptosis through a mitochondrial/caspase pathway in 
human promonocytic U937 cells. Toxicology In Vitro 21:25-31. 
KIM, S., T.]. LEE,]. LEEM, K. S. CHOI,]. W. PARK, and T. K. 
KWON. 2008. Sanguinarine-induced apoptosis: generation of ROS, 
down-regulation of Bcl-2, c-FLIP, and synergy with TRAIL. Journal 
of Cellular Biochemistry 104:895-907. 
LARSSON, D., S. HASSAN, R. LARSSON, K. OBERG, and D. 
GRANBERG. 2009. Combination analysis of anti-cancer drugs on 
human neuroendocrine tumor cell lines. Cancer Chemotherapy and 
Pharmacology 65:5-12. 
LEE,]. S., W. K.JUNG, M. H.JEONG, T. R. YOON, and H.K. KIM. 
2012. Sanguinarine induces apoptosis ofHT-29 human colon cancer 
cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent 
pathway. International Journal of Toxicology 31: 70-77. 
MAZZIO, E. A. and K. F. SOLIMAN. 2009. In vitro screening for the 
tumoricidal properties of international medicinal herbs. Phytotherapy 
Research 23:385-398. 
MISHRA, V., D. K. SAXENA, and M. DAS. 2009. Effect of argemone 
oil and argemone alkaloid, sanguinarine, on Sertoli-germ cell 
coculture. Toxicology Letters 186:104-110. 
MORAN, A. M. and K. F. HELM. 2008. Histopathologic findings and 
diagnostic difficulties posed with use of escharotic agents for 
treatment of skin lesions: a case report and review of the literature. 
Journal of Cutaneous Pathology 35:404-406. 
PAZHANG, Y., S. AHMADIAN, M. MAHMOUDIAN, and M. 
SHAFIEZADEH. 2011. Berberine-induced apoptosis via decreasing 
the surviving protein in K562 cell line. Medical Oncology 
28:1577-1583. 
PHILOGENE, B. J. R., ]. T. ARNSON, G. H. N. TOWERS, Z. 
ABRAMOWSKI, F. CAMPOS, D. CHAMPAGNE, and D. MCLA-
CHLAN. 1984. Berberine: a naturally occurring phototoxic alkaloid. 
Journal of Chemical Ecology 10:115-123. 
SENCHINA, D. S., G. N. FLINN, D. A. MCCANN, M. L. KOHUT, 
and C. T. SHEARN. 2009a. Bloodroot (Sanguinaria canadensis L., 
Papaveraceae) enhances proliferation and cytokine production by 
human peripheral blood mononuclear cells in an in vitro model. 
Journal of Herbs, Spices, and Medicinal Plants 15:45-65. 
SENCHINA, D. S., ]. E. HALLAM, A. S. DIAS, and M. A. PERERA. 
2009b. Human blood mononuclear cell in vitro cytokine response 
before and after two different strenuous exercise bouts in the presence 
of bloodroot and echinacea extracts. Blood Cells, Molecules, and 
Diseases 43:298-303. 
SENCHINA, D. S., ]. E. HALLAM, N. M. THOMPSON, N. A. 
NGUYEN, J. R. ROBINSON, and M.A. D. N. PERERA. 2012. 
Alkaloids and endurance athletes. Track and Cross Country Journal 
2:2-18. 
TAKEMURA, T., N. IKEZAWA, K. IWASA, and F. SATO. 2010. 
Metabolic diversification of benzylisoquinoline alkaloid biosynthesis 
through the introduction of a branch pathway in Eschscholzia 
californica. Plant Cell Physiology 51 :949-959. , 
VECERA, R., B. KLEDJUS, P. KOSINA,J. OROLIN, M. STIBOROVA, 
S. SMRCEK,J. VICAR, Z. DVORAK,]. ULRICHOV A, V. KUBAN, 
P. ANZENBACHER, and V. SIMANEK. 2007. Disposition of 
sanguinarine in the rat. Xenobiotica 37:549-558. 
VLACHOJANNIS, C., F. MAGORA, and S. CHRUBASIK. 2012. Rise 
and fall of oral health products with Canadian bloodroot extract. 
Phytotherapy Research 26:1423-1426. 
VOGLER, M., K. WEBER, D. DINSDALE, I. SCHMITZ, K. 
SCHULZE-OSTHOFF, M. ]. DYER, and G. M. COHEN. 2009. 
Different forms of cell death induced by putative BCL2 inhibitors. 
Cell Death and Differentiation 16:1030-1039. 
VRBA, J., P. DOLEZEL, J. VICAR, and ]. ULRICHOVA. 2009. 
Cytotoxic activity of sanguinarine and dihydrosanguinarine in human 
promyelocytic leukemia HL-60 cells. Toxicology In Vitro 
23:580-588. 
WANG, M. Z. and E. M. WARSHAW. 2012. Bloodroot. Dermatitis 
23:281-283. 
ZDARILOV A, A., ]. MALIKOV A, Z. DVORAK, ]. ULRICHOV A, 
and V. SIMANEK. 2006. Quaternary isoquinoline alkaloids 
sanguinarine and chelerythrine: in vitro and in vivo effects. Chemike 
Listy 100:30-41. 
